Biohaven Ltd. ( BHVN ) shares are trading higher premarket on Monday after the company disclosed that it has entered into an agreement with Oberland Capital Management LLC to invest up to $600 million.

The investment is structured through a non-dilutive Note Purchase Agreement (NPA). The first tranche of $250 million in gross proceeds is expected to be funded at closing on or before April 30, 2025.

Following FDA approval of troriluzole, Biohaven ( BHVN ) may draw an additional $150 million at its option, while another $200 million could be made available upon mutual agreement for strategic acquisitions and related expenses, subject to specific conditions.

Also Read: Strong Immunoglobulin Reduction Data Positions Biohaven’s BHV-1300 As Potential Autoimmune Therapy

The NPA also grants Oberland a right to regulatory milestone payments through 2030 and tiered single-digit royalties on global net sales of troriluzole for up to 10 years, capped at a predetermined multiple of the invested amount.

The additional funding is expected to bolster Biohaven's ( BHVN ) clinical trial programs across its development portfolio and support commercialization initiatives ahead of a potential U.S. FDA approval of troriluzole for spinocerebellar ataxia (SCA), a group of rare, progressively debilitating, and fatal genetic disorders currently lacking approved treatments.

As of Dec. 31, cash, cash equivalents, marketable securities and restricted cash stood at around $489 million.

Investors can gain exposure to the stock via Simplify Health Care ETF ( PINK ) and iShares Trust iShares Neuroscience and Healthcare ETF .

Price Action: Biohaven ( BHVN ) shares are up 5.85% at $21.00 premarket at the last check Monday.

Read Next:

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data